Figure 1
The KIAA1199 transcript and protein expression and correlation to clinical outcome. (A) The KIAA1199 transcript profiling of 511 colon samples (normal mucosas, MSS microsatellite stable and MSI instable and adenocarcinomas). (a) The U133A GeneChips (n=122); (b) U133plus2.0 GeneChips (n=389); (details shown in Supplementary Figure 1). (B) Normal colon mucosa showed a very weak expression in the cytoplasm of single cells located in the bottom of the crypts. (C) Western Blot of SW480 cells overexpressing KIAA1199-V5-HIS protein (157 kDa). Lane 1 – Marker Bio-Rad All Blue; lane 2 – the monospecific rabbit polyclonal anti-KIAA1199 antibody was specific for KIAA1199 (specificity is shown in Supplementary Figures 2a and b). (D) Immunohistochemical analysis of 270 stage II adenocarcinomas (>3 years follow-up) using the monospecific anti-KIAA1199 antibody: group 1 showed strong nuclear but weak cytoplasmic KIAA1199 expression, group 2 showed moderate to strong cytoplasmic KIAA1199 expression, no nuclear expression. (E) In all 245 of the 270 samples were informative (118 female, 127 male). Patients without disease recurrence (n=205, median follow-up time 2198 days, range 1099–4368); patients with metastatic recurrence (n=40, median time to recurrence 830 days, range 95–2449). Kaplan–Meier survival estimates for disease-free survival showed that patients with group 1 tumours (blue line) had a significant (log-rank test P-value 0.02) better outcome than group 2 patients (red line). Green ticks: patients censored at death or end of follow-up.
